Use: Treatment of idiopathic hypersomniaUsual Pediatric Dose for Narcolepsy (7 years and older)Less than 20 kg:Specific dosing recommendations are not available.20 to less than 30 kg:Initial dose: Up to 2 g orally per day, divided and given as 2 equal doses of up to 1 g/dose...
The safety and effectiveness of XYWAV for the treatment of cataplexy or excessive daytime sleepiness in pediatric patients 7 years of age and older with narcolepsy have been established. XYWAV has not been studied in a pediatric clinical trial for narcolepsy or IH. Use of XYWAV in pediatric pati...
Food and Drug Administration (FDA) approved Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution on July 21, 2020 for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.1,2 Xywav is ...